​

Immunome (IMNM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IMNM Stock Forecast

Immunome (IMNM) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $23.00, with a high of $23.00 and a low of $23.00. This represents a 145.99% increase from the last price of $9.35.

$5 $9 $13 $17 $21 $25 High: $23 Avg: $23 Low: $23 Last Closed Price: $9.35

IMNM Stock Rating

Immunome stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

IMNM Forecast vs Benchmarks

TypeNameUpside
StockImmunome145.99%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$30.33
Last Closing Price$9.35$9.35$9.35
Upside/Downside--224.39%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2525---7
Dec, 2425---7
Nov, 2435---8
Oct, 2434---7
Sep, 2434---7
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 13, 2024Biren AminPiper Sandler$23.00$12.6481.96%145.99%
Apr 15, 2024Michael SchmidtGuggenheim$35.00$20.5870.07%274.33%
Apr 01, 2024David NierengartenWedbush$33.00$24.6833.71%252.94%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 14, 2024Piper SandlerOverweightOverweighthold
Sep 16, 2024Cowen & Co.BuyBuyhold
Aug 13, 2024Piper SandlerOverweightOverweighthold
May 31, 2024Piper SandlerOverweightinitialise
Apr 15, 2024GuggenheimBuyinitialise
Apr 01, 2024WedbushOutperformOutperformhold

Financial Forecast

EPS Forecast

$-20 $-16 $-12 $-8 $-4 $0 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.05$-5.38-----
Avg Forecast$-8.63$-0.92$-4.42$-3.11$-3.21$-2.81$-1.32
High Forecast$-15.99$-1.19$-4.56$-4.10$-4.36$-3.97$-1.63
Low Forecast$-3.99$-0.47$-4.32$-2.48$-2.36$-1.72$-1.01
Surprise %-41.48%484.78%-----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$14.02M-----
Avg Forecast$2.10M$12.27M$9.41M$3.15M$17.90M$76.14M$223.12M
High Forecast$1.23M$10.50M$7.56M$2.58M$17.90M$76.14M$183.11M
Low Forecast$3.48M$14.02M$11.40M$3.71M$17.90M$76.14M$262.84M
Surprise %-14.28%-----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-17.12M$-106.81M-----
Avg Forecast$-171.25M$-16.47M$-88.13M$-65.26M$-66.63M$-56.45M$-26.19M
High Forecast$-317.26M$-23.53M$-90.47M$-81.35M$-86.51M$-78.77M$-32.26M
Low Forecast$-79.25M$-9.41M$-85.78M$-49.16M$-46.75M$-34.13M$-20.09M
Surprise %-90.00%548.56%-----

IMNM Forecast FAQ

Is Immunome stock a buy?

Immunome stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Immunome is a favorable investment for most analysts.

What is Immunome's price target?

Immunome's price target, set by 4 Wall Street analysts, averages $23 over the next 12 months. The price target range spans from $23 at the low end to $23 at the high end, suggesting a potential 145.99% change from the previous close price of $9.35.

How does Immunome stock forecast compare to the average forecast of its sector, industry, and investment themes?

Immunome stock forecast shows a 145.99% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Immunome over the past three months?

  • January 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Immunome’s EPS forecast?

Immunome's average annual EPS forecast for its fiscal year ending in December is -4.42 for 2024, a -17.84% decrease from the reported $-5.38 in 2023. The prediction for 2025 is $-3.11, $-3.21 for 2026, $-2.81 for 2027, and $-1.32 for 2028.

What is Immunome’s revenue forecast?

Immunome's average annual revenue forecast for its fiscal year ending in December is $9.41M for 2024, a -32.90% decrease from the reported $14.02M in 2023. The forecast for 2025 is $3.15M, $17.9M for 2026, $76.14M for 2027, and $223.12M for 2028.

What is Immunome’s net income forecast?

For its fiscal year ending in December, Immunome's average annual net income forecast is $-88.125M for 2024, reflecting a -17.49% decrease from the reported $-107M in 2023. The projection for 2025 is $-65.257M, $-66.63M for 2026, $-56.449M for 2027, and $-26.194M for 2028.